近期，公司已将上述现金管理产品赎回，收回本金7,000万元，取得实际收益47.44万元， 与预期收益不存在重大差异。 二、关联关系说明 证券代码：300463 证券简称：迈克生物 公告编号：2024-045 迈克生物股份有限公司 关于使用部分闲置募集资金进行现金管理 到期赎回的进展公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、误导性 陈述或者重大遗漏。 迈克生物股份有限公司第五届董事会第十三次会议、第五届监事会第十二次会议审议通过 了《关于继续使用部分闲置募集资金进行现金管理的议案》，为提高暂时闲置募集资金的使用 效率，增加资金收益，在保证募集资金投资项目建设和募集资金正常使用的情况下，同意使用 不超过人民币15,000万元的暂时闲置募集资金进行现金管理，用于购买安全性高、流动性好、 满足保本要求的理财产品，自公司第五届董事会第十三次会议审议通过之日起十二个月内有效， 在上述使用期限及额度内，资金可以循环滚动使用。闲置募集资金现金管理到期后将及时归还 至募集资金专户，同时授权公司董事长行使相关投资决策权，财务负责人办理具体相关事宜。 公司已于2024年3月11日在巨潮资讯网刊登了《 ...

Financial Performance - The company's revenue for Q1 2024 was ¥616,367,154.02, representing a decrease of 8.88% compared to ¥676,400,369.15 in the same period last year[5] - Net profit attributable to shareholders was ¥120,442,248.90, an increase of 3.05% from ¥116,873,753.42 year-on-year[5] - Basic earnings per share increased by 5.26% to ¥0.20, compared to ¥0.19 in the previous year[5] - Total operating revenue for Q1 2024 was CNY 616,367,154.02, a decrease of 8.9% compared to CNY 676,400,369.15 in the same period last year[21] - Net profit for Q1 2024 increased to CNY 124,243,826.11, compared to CNY 117,826,419.32 in Q1 2023, reflecting a growth of 5.9%[22] - The net profit attributable to the parent company for Q1 2024 was ¥120,442,248.90, an increase from ¥116,873,753.42 in Q1 2023, representing a growth of approximately 2.2%[23] - The total comprehensive income attributable to the parent company was ¥120,078,599.54, compared to ¥108,540,535.42 in the previous year, indicating an increase of about 10.5%[23] - The basic and diluted earnings per share for Q1 2024 were both ¥0.20, up from ¥0.19 in Q1 2023, reflecting a growth of approximately 5.3%[23] Cash Flow - The net cash flow from operating activities significantly dropped by 97.08%, from ¥167,046,659.56 to ¥4,884,287.66[11] - The net cash flow from operating activities was ¥4,884,287.66, a significant decrease from ¥167,046,659.56 in the same period last year[26] - Cash inflow from operating activities totaled ¥765,844,742.92, down from ¥925,552,026.14, marking a decline of about 17.3%[26] - Cash outflow from operating activities was ¥760,960,455.26, slightly up from ¥758,505,366.58, resulting in a marginal increase of approximately 0.2%[26] - The net cash flow from investing activities was -¥39,461,178.86, compared to ¥31,799,722.54 in the previous year, indicating a decline in cash flow from investments[26] - The net cash flow from financing activities was ¥16,166,025.50, down from ¥21,161,398.67, reflecting a decrease of about 23.5%[26] - The total cash and cash equivalents decreased by ¥18,243,411.78 during the quarter, contrasting with an increase of ¥219,019,154.78 in the same period last year[26] - The company received tax refunds amounting to ¥21,428,623.41, a significant increase from ¥1,678,971.78 in the previous year, showing a growth of approximately 1,177.5%[26] Assets and Liabilities - Total assets at the end of the reporting period were ¥8,124,498,732.44, a slight increase of 0.06% from the previous year[5] - The company's total assets as of Q1 2024 amounted to CNY 8,124,498,732.44, slightly up from CNY 8,119,249,307.93 in the previous quarter[19] - Current liabilities decreased to CNY 1,082,471,807.86 from CNY 1,120,605,110.52 in the previous quarter, a reduction of 3.4%[19] - The total liabilities decreased to CNY 1,412,015,783.97 from CNY 1,507,787,287.39, a decline of 6.3%[19] - The company's total equity increased to CNY 6,712,482,948.47 from CNY 6,611,462,020.54, reflecting a growth of 1.5%[19] Shareholder Information - The total number of common shareholders at the end of the reporting period is 38,606[12] - The largest shareholder, Tang Yong, holds 11.11% of shares, totaling 68,062,301 shares, with 17,700,000 shares pledged[12] - The top ten shareholders hold a combined total of 68.67% of the shares[12] Business Operations - The company has initiated the transition from direct sales to distribution, completing the transfer of direct sales business in the Chongqing area[14] - The company plans to deregister its wholly-owned subsidiary, Beijing Dami Microbiology Technology Co., Ltd., which has no operational business as of September 30, 2023[14] - The company has completed the acquisition of 100% equity in Beijing Dami Microbiology Technology Co., Ltd. in phases since November 2020 and March 2022[14] - The company has no significant impact on its overall business development and profitability from the deregistration of Beijing Dami Microbiology[14] Market Outlook - The company emphasizes the positive future outlook for the molecular diagnostics sector and digital PCR technology applications[14] Financial Metrics - Financial expenses decreased by 38.48% to ¥3,828,016.16, attributed to lower interest expenses and increased foreign exchange gains[10] - Investment income fell by 51.15% to ¥1,850,226.43, due to a decline in returns from wealth management products[10] - The company’s weighted average return on equity was 1.87%, slightly up from 1.84% year-on-year[5] - Research and development expenses for Q1 2024 were CNY 59,524,079.57, slightly up from CNY 58,345,527.09 in Q1 2023[22] - The company reported a decrease in financial expenses to CNY 3,828,016.16 from CNY 6,222,293.94 in the previous year, a reduction of 38.5%[22] - The company reported a 54.84% decrease in trading financial assets, primarily due to the redemption of bank wealth management products[9]

Regional Revenue Breakdown - Northeast region revenue: 225,520,785.38 RMB, accounting for 7.79% of total revenue[1] - North China region revenue: 331,306,222.13 RMB, accounting for 11.44% of total revenue[1] - East China region revenue: 517,166,191.62 RMB, accounting for 17.86% of total revenue[1] - Central China region revenue: 226,862,637.73 RMB, accounting for 7.83% of total revenue[1] - South China region revenue: 182,913,613.90 RMB, accounting for 6.32% of total revenue[1] - Northwest region revenue: 219,220,451.56 RMB, accounting for 7.57% of total revenue[1] - Southwest region revenue: 1,090,898,703.75 RMB, accounting for 37.67% of total revenue[1] - Overseas region revenue: 101,880,905.95 RMB, accounting for 3.52% of total revenue[1] Sales Channels - Direct sales revenue: 1,056,481,998.80 RMB, accounting for 36.48% of total revenue[1] - Distribution sales revenue: 1,839,287,513.22 RMB, accounting for 63.52% of total revenue[1] Product Development and R&D - The company has established a "8+1" product technology platform, including biochemistry, immunity, blood cells, coagulation, urine, molecular, blood type, pathology, and rapid testing, with 512 registered certificates for self-developed in vitro diagnostic products[22] - In 2023, the company completed the development of 30 raw materials, including 19 antibodies, 6 antigens, and 5 chemical raw materials, with a self-sufficiency rate of core raw materials exceeding 50%[22] - The company added 64 new products during the reporting period, bringing the total number of registered products to 512[28] - The company completed 71 R&D projects in 2023, with 572 projects still in progress, and invested a total of 414.02 million yuan in R&D[40] - The company's R&D team consists of 1,172 personnel, with 577 focused on clinical testing and 595 on other diagnostic areas[40] - The company's R&D investment increased by 22.34% to 414 million yuan, with R&D personnel growing by 149 to 1,172, accounting for 34.86% of total employees[88] - The company obtained 64 new domestic product registrations in 2023, bringing the total to 512, including 485 reagents and 27 instruments[119] - The company launched the LABAS MIX fully automated laboratory intelligent assembly line, integrating ten functions such as automatic quality control detection and multi-mode sample input[119] - The company added 19 new reagent product registrations for its acridinium ester direct chemiluminescence technology platform, bringing the total to 102[119] Financial Performance - The company's revenue for the four quarters of 2023 were 676.4 million, 704.3 million, 734.4 million, and 780.7 million respectively[29] - The net profit attributable to shareholders for the four quarters of 2023 were 116.9 million, 58.0 million, 93.8 million, and 43.9 million respectively[29] - The net cash flow from operating activities for the four quarters of 2023 were 167.0 million, 242.7 million, 207.4 million, and 284.4 million respectively[29] - The company's revenue for the reporting period was 2.896 billion yuan, a year-on-year decrease of 19.75%, with net profit attributable to shareholders of 313 million yuan, a year-on-year decrease of 55.86%[61] - Total operating revenue for 2023 was RMB 2,895,769,512.02, a decrease of 19.75% compared to 2022[62] - Revenue from self-developed products accounted for 64.94% of total revenue, amounting to RMB 1,880,368,645.95, a decrease of 18.67% year-over-year[62] - Revenue from agent products was RMB 981,448,342.17, accounting for 33.89% of total revenue, a decrease of 21.87% compared to 2022[62] - The company's net profit was 212,756,122.56, compared to 368,913,140.91 in the previous period[108] - The company's total comprehensive income was 199,197,097.20, compared to 384,841,761.44 in the previous period[108] - Revenue for 2023 was 2,895.77 million yuan, a decrease of 19.75% compared to the previous year[144] Market Expansion and Distribution - The company's self-developed products cover over 8,000 medical institutions nationwide, with coverage rates of 24% in secondary hospitals and 50% in tertiary hospitals[35] - The company has established partnerships with 566 distributors, and its products are available in 118 countries and regions, with overseas markets becoming a key focus for expansion[35] - The company has invested in overseas market expansion, setting up 2 overseas platform companies, 1 overseas office, and 1 overseas transit warehouse, with products covering 118 countries and regions[50] - The company has a wide marketing service network, with 12 channel subsidiaries, 17 offices, and 622 sales personnel in the domestic market, serving over 8,000 terminal customers[59] Product Sales and Inventory - The company's autonomous products achieved sales revenue of 1.714 billion yuan, a year-on-year increase of 4.92%, with 4,016 large instruments and production lines shipped to the terminal market[58] - Sales of immunodiagnostic reagents reached RMB 952 million, an increase of 18.68% year-over-year[70] - Sales of biochemical reagents were RMB 577 million, an increase of 2.54% year-over-year[70] - Sales of molecular diagnostic reagents dropped significantly to RMB 7.0451 million, a decrease of 98.79% year-over-year[70] - Inventory balance decreased by 12.7% at the end of 2023 compared to the previous year[71] - Accounts receivable balance decreased by 14.48% at the end of 2023 compared to the previous year[71] - Revenue from in vitro diagnostic products decreased by 19.75% to 2,895,769,512.02 yuan, with a gross margin of 55.27%[73] - Sales volume of diagnostic reagents dropped by 44.47% to 3.3274 million boxes, while production volume decreased by 44.57% to 3.1403 million boxes[73] - Sales volume of diagnostic instruments (large type) increased by 4.43% to 3,462 units, with production volume rising by 18.82% to 3,555 units[73] - Sales volume of diagnostic assembly lines surged by 122.15% to 351 units, with production volume increasing by 107.03% to 383 units[73] - The company achieved a total of 4,016 units (lines) of large instruments and assembly lines delivered to the market, including 189 biochemical and immune assembly lines and 162 blood assembly lines[74] - The company's diagnostic assembly line inventory increased by 77.5% to 71 units, driven by the promotion of full laboratory automation assembly lines[89] Financial Position and Assets - The company's debt-to-asset ratio decreased to 18.57% by the end of the reporting period, a reduction of 1.49 percentage points compared to the previous year[42] - The company's financing costs decreased by 7% year-on-year, with short-term and long-term loan ratios adjusted to 29%[42] - Cash and cash equivalents at the end of the period increased to 811,362,294.43 yuan, up from 564,293,033.08 yuan at the beginning of the period[110] - Net cash flow from financing activities was -152,750,581.74 yuan, compared to 930,049,187.87 yuan in the previous period[110] - Total assets at the end of the period were 8,119,249,307.93 yuan, slightly down from 8,168,350,292.26 yuan at the beginning of the period[126] - Fixed assets increased to 2,186,644,511.57 yuan from 1,979,045,213.17 yuan[126] - Short-term borrowings decreased to 144,647,498.10 yuan from 248,075,777.91 yuan[126] - The company's total equity at the end of the period was 6,611.462 million yuan[137] - The company allocated 28 million yuan for surplus reserves[135] - The company distributed 286.635 million yuan to shareholders[135] - The company's capital reserve increased by 973,812.19 yuan[135] - The company's total assets at the end of the period were 6,384.825 million yuan[137] - Inventory increased to 531,716,615.34 from 511,178,091.88, reflecting a growth of 4.02%[151] - Total current assets decreased to 4,612,719,595.24 from 4,750,174,683.29, a decline of 2.89%[151] - Long-term equity investments decreased to 1,011,979,841.96 from 1,030,817,115.07, a reduction of 1.83%[151] - Fixed assets increased significantly to 1,090,901,724.56 from 643,509,759.96, a growth of 69.53%[151] - Development expenditure rose to 35,090,057.08 from 26,227,525.22, an increase of 33.79%[151] - Cash received from sales of goods and services increased to 1,750,685,765.23 from 1,577,681,416.05, a growth of 10.97%[156] - Net cash flow from operating activities surged to 852,137,792.51 from 479,718,443.09, an increase of 77.63%[156] - Cash outflow for investments decreased to 2,608,658,144.10 from 3,305,095,470.26, a reduction of 21.07%[156] - Cash received from tax refunds increased significantly to 67,558,608.47 from 3,573,372.16, a growth of 1790.47%[156] - Total assets increased to 7,106,384,593.18 from 6,809,623,435.59, a growth of 4.36%[151] Corporate Governance and Shareholders - The company has 20 wholly-owned or controlled subsidiaries, including 12 domestic trading companies and 2 overseas trading companies, with R&D functions distributed across Chengdu, Hangzhou, Beijing, and the US[35] - The company released 80 temporary announcements and completed 59 investor research sessions in 2023[100] - The company's board consists of 9 members, including 3 independent directors[103] - The total restricted shares at the end of the reporting period were 117,119,807[104] - The number of ordinary shareholders at the end of the reporting period was 39,869, up from 38,606 at the end of the previous month[115] - The China Construction Bank-Huabao CSI Medical ETF exited the top ten shareholders, while the China Construction Bank-GF Healthcare Equity Fund was newly added[131] Quality Management and Traceability - The company has established a comprehensive quality management system, including 100,000-level clean rooms for microbial testing and barcode management for full traceability of product quality[49] - The company has established a leading metrological traceability system in the industry, being the first Chinese enterprise representative in the JCTLM international metrological traceability system[54] Product Line and Strategy - The company's products include a wide range of diagnostic platforms, such as biochemistry, immunology, hematology, and molecular diagnostics, with integrated automation solutions[34] - The company has a complete product line strategy, covering biochemical, immunological, hematological, molecular diagnostics, POCT, pathology, and raw materials, making it one of the most comprehensive IVD companies in China[54] Cost Management and Supply Chain - The company focuses on cost management, optimizing supply chain procurement and increasing the self-production rate of raw materials to reduce production costs[46] Guarantees and Subsidiaries - The total approved guarantee amount for subsidiaries during the reporting period was 143,000[95] - The actual guarantee amount issued during the reporting period was 45,022.77[95] - The total approved guarantee amount for subsidiaries at the end of the reporting period was 93,000[98] - The actual guarantee balance for subsidiaries at the end of the reporting period was 6,522.77[98] Financial Assets and Liabilities - The company's financial liabilities are initially classified as either financial liabilities measured at fair value through profit or loss or financial liabilities measured at amortized cost[181] - Financial assets measured at amortized cost include interest calculated using the effective interest method during the holding period, which is recognized in current profit or loss[183] - Financial assets measured at fair value through other comprehensive income (equity instruments) are initially measured at fair value, with related transaction costs recognized in current profit or loss[184] - Financial liabilities measured at fair value through profit or loss are initially measured at fair value, with related transaction costs recognized in current profit or loss[184] - The company terminates recognition of existing financial liabilities when substantial modifications are made to the contract terms, and the modified financial liability is recognized as a new financial liability[186] - The company measures the loss allowance for receivables at an amount equal to the lifetime expected credit losses, regardless of whether they contain a significant financing component[187] - The company's financial assets are initially classified as financial assets measured at amortized cost, financial assets measured at fair value through other comprehensive income (debt instruments), or financial assets measured at fair value through profit or loss[193] - Financial assets measured at fair value through other comprehensive income (debt instruments) are initially measured at fair value, with related transaction costs included in the initial recognition amount[196] - Upon derecognition, the cumulative gain or loss previously recognized in other comprehensive income is reclassified from other comprehensive income to retained earnings[197] - The difference between the consideration paid and the carrying amount of the financial liability is recognized in current profit or loss upon derecognition[198] Acquisitions and Equity Transfers - The company transferred 100% equity of Xinjiang Mike for 10.3852 million yuan on August 8, 2023[146] - The company acquired 100% equity of Beijing Dawei Microorganism Technology Co., Ltd. in November 2020 and March 2022[146] - As of September 30, 2023, Dawei Microorganism had no operational business and was planned for deregistration[146]

独立董事 2023 年度述职报告 第 1 页 共 11 页 独立董事独立性的情况，符合《上市公司独立董事管理办法》《深圳证券交易所上市公司自律监管 指引第 2 号——创业板上市公司规范运作》（以下简称"《创业板上市公司规范运作》"）等法律、 法规、规范性文件及《公司章程》《独立董事工作制度》等规章制度中关于独立董事独立性的相关 要求。 二、出席会议情况 2023 年度本人出席会议的情况如下： 各位股东及股东代表： 作为迈克生物股份有限公司（以下简称"公司"）第五届董事会独立董事，2023 年度，本人严 格按照《公司法》《证券法》等法律、法规、规范性文件和《公司章程》《独立董事工作制度》 的相关规定，诚信、勤勉、尽责、忠实地履行职责，积极出席相关会议，对各项议案进行认真审 议，对公司重大事项发表了独立意见，充分发挥了独立董事及各专业委员会委员的作用。一方面， 严格审核公司提交董事会的相关事项，维护公司和股东的合法权益，促进公司规范运作；另一方 面发挥自身的专业优势，积极关注和参与研究公司的发展，为公司的内部控制、薪酬激励等工作 提出了意见和建议。 现就本人 2023 年度履行独立董事职责情况汇报如下： 一、本人 ...

证券代码:300463 证券简称:迈克生物 公告编号:2024-040 迈克生物股份有限公司 关于 2024 年度公司及子公司向金融机构申请 授信额度的公告 根据公司生产经营的需要，为满足公司及合并报表范围内子公司生产经营的资金需求，保 障公司稳健运营，2024 年度公司拟向金融机构申请不超过人民币 27.5 亿元的综合授信额度及 项下业务，其中包含以位于成都市高新区百川路 16 号的土地房产继续为向中国银行股份有限 公司成都蜀都支行申请的敞口授信额度及项下业务提供抵押担保不超过人民币 3.5 亿元，该授 信额度包括新增授信及原有授信的展期或者续约，授信项下业务包含但不限于流动资金贷款、 各类保函、信用证、应收账款保理、贸易融资、银行承兑汇票、商业承兑汇票、置换其他机构 贷款等，授信额度不等于公司的实际融资金额，以金融机构与公司及子公司实际发生的融资金 额为准，具体融资金额将视公司及子公司的实际需求确定。 公司及合并报表范围内子公司 2024 年度预计向银行等金融机构申请的综合授信额度具体 情况如下： | 序号 | 机构名称 | 申请授信额度（亿元） | 额度期限 | | --- | --- | --- | ...

迈克生物股份有限公司 章程 二○二四年四月 目 录 第 1 页 共 41 页 第一章 总则 第二章 经营宗旨和范围 第三章 股份 第一节 股份发行 第二节 股份增减和回购 第三节 股份转让 第四章 股东和股东大会 第一节 股东 第二节 股东大会的一般规定 第三节 股东大会的召集 第四节 股东大会的提案与通知 第五节 股东大会的召开 第六节 股东大会的表决和决议 第五章 董事会 第一节 董事 第二节 董事会 第六章 总经理及其他高级管理人员 第七章 监事会 第一节 监事 第二节 监事会 第八章 财务会计制度、利润分配和审计 第一节 财务会计制度 第二节 内部审计 第三节 会计师事务所的聘任 第九章 通知与公告 第一节 通知 第二节 公告 第十章 合并、分立、增资、减资、解散和清算 第一节 合并、分立、增资和减资 第 2 页 共 41 页 第二节 解散和清算 第十一章 修改章程 第十二章 特别规定 第十三章 附则 第一章 总则 第一条 为维护公司、股东和债权人的合法权益，规范公司的组织和行为，根据《中华 人民共和国公司法》（以下简称《公司法》）、《中华人民共和国证券法》（以下简称《证 券法》）和其他有关规定，制订 ...

迈克生物股份有限公司 2024 年度董事、监事、高级管理人员薪酬与考核方案 第一章 总则 第一条 为了更好地调动迈克生物股份有限公司（以下简称"公司"）董事、监事、高级管理 人员的工作积极性，建立与现代企业制度相适应的激励约束机制，保持核心管理团队的稳定性， 提升公司的经营管理效益和效率，依据《公司法》《上市公司治理准则》《公司章程》等规定，结 合公司经营规模、业绩等实际情况，参考行业特点，特制订本方案。 第二条 本方案适用于公司董事、监事及高级管理人员。 第三条 本方案所称董事，是指本方案执行期间公司董事会的全部在职成员，包括内部董事、 外部董事及独立董事。 本方案所称监事，是指方案执行期间公司监事会的全部在职成员，包括内部监事和外部监事。 内部监事，是指与公司之间签订聘任合同或劳动合同的公司员工或公司管理人员兼任的监事（包 括职工监事）。外部监事，指不在公司担任除监事外的其他职务的监事。 本方案所称高级管理人员，是指总经理、财务总监、研发总监、市场运营总监、商务总监、 生产总监、行政总监、战略投资总监、董事会秘书等高级管理人员。 第四条 2024 年董事、监事及高级管理人员的薪酬方案以公司经济效益为出发点 ...

证券代码:300463 证券简称:迈克生物 公告编号:2024-043 迈克生物股份有限公司 关于部分募投项目子项目变更及金额调整 并进行部分募投项目延期的公告 证券代码:300463 证券简称:迈克生物 公告编号:2024-043 一、募集资金基本情况 经中国证券监督管理委员会《关于同意迈克生物股份有限公司向特定对象发行股票注册 的批复》（证监许可〔2021〕412 号）的核准，迈克生物股份有限公司本次向特定对象发行 人民币普通股（A 股）56,000,000 股，每股面值 1 元，发行价格为 28.11 元/股，募集资金总 额为人民币 1,574,160,000.00 元，扣除发行费用人民币（不含增值税）16,703,564.36 元，实际 募集资金净额为人民币 1,557,456,435.64 元。2022 年 1 月 25 日，招商证券股份有限公司将扣 除保荐机构（联席主承销）保荐承销费 15,741,600.00 元（含增值税）后的上述认购资金的剩 余款项人民币 1,558,418,400.00 元划转至公司本次向特定对象发行开立的募集资金专项存储账 户中。立信会计师事务所（特殊普通合伙）已对募集资 ...

证券代码:300463 证券简称:迈克生物 公告编号:2024-041 迈克生物股份有限公司 关于公司 2024 年度为子公司提供担保额度预计的公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、误导性 陈述或者重大遗漏。 重要内容提示： 迈克生物股份有限公司（以下简称"迈克生物"、"公司"）于2024年4月24日召开第五届董事 会第十四次会议及第五届监事会第十三次会议，审议通过了《关于2024年度公司向金融机构申 请综合授信额度及项下业务并为子公司申请综合授信额度及项下业务担保的议案》《关于全资 子公司增加向金融机构申请项目贷款额度并由公司提供担保的议案》，同意为公司全资子公司 迈克医疗电子、安可瑞新材料向金融机构申请综合授信额度提供担保，担保额度为人民币1.8 亿元；为公司全资子公司迈克医疗科技向指定银行申请增加项目贷款授信额度2亿元提供担保。 上述2项议案尚需提交公司股东大会审议。现将具体内容公告如下： 一、公司本次为子公司提供担保的情况概述 （一）为子公司申请综合授信额度提供担保的情况 为支持子公司发展，提高子公司贷款和融资效率，在综合分析子公司盈利能力、偿债能 力和风险控制能力 ...

招商证券股份有限公司 关于迈克生物股份有限公司 部分募投项目子项目变更及金额调整 并进行部分募投项目延期的核查意见 招商证券股份有限公司（以下简称"招商证券"）作为迈克生物股份有限公司 （以下简称"迈克生物"、"公司"）向特定对象发行股票的保荐机构，根据《证券 发行上市保荐业务管理办法》《上市公司监管指引第 2 号—上市公司募集资金管 理和使用的监管要求》《深圳证券交易所创业板股票上市规则》《深圳证券交易所 上市公司自律监管指引第 2 号—创业板上市公司规范运作》及《深圳证券交易所 上市公司自律监管指引第 13 号—保荐业务》等有关规定，对公司部分募投项目 子项目变更及金额调整并进行部分募投项目延期情况进行了核查，具体情况如下： 一、 变更募集资金投资项目的概述 （一）募集资金基本情况 经中国证券监督管理委员会《关于同意迈克生物股份有限公司向特定对象发 行股票注册的批复》（证监许可〔2021〕412 号）的核准，公司本次向特定对象发 行人民币普通股（A 股）56,000,000 股，每股发行价格为 28.11 元/股，募集资金 总额为人民币 1,574,160,000.00 元，扣除发行费用人民币（不含增值税 ...